Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC005 Phase Ia Study in Healthy Subjects
NCT05138770Phase 1Completed
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VC-005 in inflammatory bowel disease (IBD) (3 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Peak Plasma Concentration at Day 4, Area under the plasma concentration versus time curve at Day 4 and 3 more. Started Nov 2021; status: completed.
02
Drugs
VC-005
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT05138770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138770.